Table 4.
Amount of Bevacizumab Delivered into the Eye In Vivo Using Visulex-I: Comparing Standard Ionic Strength (Commercial Bevacizumab Formulation 25 mg/mL) Versus Low Ionic Strength (New Iontophoresis Bevacizumab Formulation 12.5 mg/mL) at Different Iontophoretic Durations; 4 mA for 5, 10, and 20 Min (Solution Volume = 500 μL, Contact Area = 2.2 cm2, n = 6)
| Formulation | Total amount delivered to eye (μg) |
||
|---|---|---|---|
| 5 min | 10 min | 20 min | |
| Standard ionic strength | 79 ± 19 | n/a | 353 ± 42 |
| Low ionic strength | 496 ± 197 | 500 ± 115 | 616 ± 317 |